Genenta Platform - Medical / Health Care

Our proprietary platform consists of dual control achieved at the transcriptional and post-transcriptional level. These ensure therapeutics are released within the tumor. A Tie-2 promoter ensures the transgene transcription occurs in TEMs, while miRNA-126 target sequences inhibit expression of the transgene in HSPCs.